

**ASX ANNOUNCEMENT****8 April 2024**

Lisa Banh  
Adviser, Listings  
Compliance ASX  
Operations  
20 Bridge Street  
SYDNEY NSW 2000

Dear Ms Banh

**SUPPLEMENTAL INFORMATION | VOLUNTARY SUSPENSION**

Medical technology company, **HeraMED Limited (ASX:HMD)** (“HeraMED” or the “Company”) requested on Friday 5 April 2024 that the securities of the Company be placed into an immediate suspension by the ASX. ASX granted that request, and the Company remains in a voluntary suspension.

For the purposes of ASX Listing Rule 17.2 and in support of its request, further information is provided to the ASX and shareholders to supplement the information announced on Friday 5 April 2024.

1. As announced to the market on Friday 5 April 2024, the voluntary suspension is necessary to assist the Company managing its continuous disclosure obligations pending an announcement in relation to changes in Directors and Management, the restructure of the business, the financial position of the Company, associated capital requirements and proposed financing to fund ongoing operations of the business.
2. As outlined in the 2023 Annual Report announced on 28 March 2024 and ASX announcement titled ‘*Result of Rights Issue and Placement*’ announced on 28 February 2024, the Company was anticipating placing the shortfall of the Rights Issue of approximately \$1,060,344 over the coming weeks. The Company has experienced challenges in placing the shortfall and as a result has led the Company to immediately consider alternative financing options.

The Company is actively engaged with third parties to secure additional funding. Successful completion of additional funding is critical to the Company’s continued financial viability. In connection with seeking to secure further funding, the Company is reviewing the structure of its business operations and associated capital requirements. In the Company’s opinion, continued trading of its securities is likely to materially prejudice its ability to complete the discussions with third parties to secure additional funding and to resolve the nature and extent of changes to its Director and Management.

3. As stated in the announcement on Friday 5 April 2024, the Company requests that the suspension remains in place until the Company releases an announcement in relation to changes in Directors and Management, the restructure of the business, the financial position of the Company, associated capital requirements and proposed financing to fund ongoing operations of the business. The discussions referred to above are ongoing, and at this stage it is difficult to predict a timetable for their conclusion however the Company is working to finalise the above matters urgently and currently intends to make that announcement by 29 April 2024. Further updates will be provided in due course.

Your faithfully

David Hinton

**-ENDS-**